Takeda Retained Earnings vs Total Liab Analysis

TAK Stock

USD 13.19 0.11 0.84%

Takeda Pharmaceutical financial indicator trend analysis is much more than just breaking down Takeda Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Takeda Pharmaceutical is a good investment. Please check the relationship between Takeda Pharmaceutical Retained Earnings and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Retained Earnings vs Total Liab

Retained Earnings vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Takeda Pharmaceutical Retained Earnings account and Total Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Takeda Pharmaceutical's Retained Earnings and Total Liab is -0.33. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Total Liab in the same time period over historical financial statements of Takeda Pharmaceutical Co, assuming nothing else is changed. The correlation between historical values of Takeda Pharmaceutical's Retained Earnings and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Takeda Pharmaceutical Co are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Retained Earnings i.e., Takeda Pharmaceutical's Retained Earnings and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.33

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Takeda Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

At this time, Takeda Pharmaceutical's Tax Provision is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.46 this year, although the value of Selling General Administrative will most likely fall to about 760.9 B.

	2021	2022	2023	2024 (projected)
Interest Expense	166.6B	169.7B	195.2B	204.9B
Depreciation And Amortization	591.5B	718.7B	826.5B	867.8B

Interest Expense Depreciation And Amortization

Takeda Pharmaceutical fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		-0.27	0.98	0.94	0.97	0.98	0.99	0.74	0.98	-0.32	0.85	0.46	1.0	-0.11	0.33	0.81	0.99	-0.57	0.98	0.99	0.92	0.95	0.99	0.92	0.9	0.51
Common Stock Shares Outstanding	-0.27		-0.11	-0.33	-0.28	-0.38	-0.39	-0.65	-0.13	-0.06	-0.62	0.18	-0.29	-0.07	0.13	-0.06	-0.22	0.08	-0.15	-0.25	-0.52	-0.15	-0.19	-0.5	0.07	0.29
Short Long Term Debt Total	0.98	-0.11		0.88	0.95	0.93	0.94	0.64	1.0	-0.34	0.74	0.5	0.98	-0.12	0.35	0.84	0.98	-0.6	0.99	0.96	0.84	0.94	1.0	0.83	0.93	0.6
Other Current Liab	0.94	-0.33	0.88		0.96	0.97	0.96	0.7	0.88	-0.35	0.93	0.34	0.95	-0.22	0.22	0.63	0.92	-0.58	0.87	0.97	0.92	0.88	0.91	0.97	0.78	0.46
Total Current Liabilities	0.97	-0.28	0.95	0.96		0.96	0.96	0.68	0.96	-0.34	0.86	0.34	0.97	-0.18	0.19	0.73	0.95	-0.62	0.93	0.98	0.92	0.89	0.96	0.91	0.84	0.63
Total Stockholder Equity	0.98	-0.38	0.93	0.97	0.96		1.0	0.79	0.93	-0.29	0.91	0.4	0.99	-0.11	0.3	0.74	0.96	-0.54	0.94	0.99	0.95	0.93	0.95	0.97	0.83	0.42
Property Plant And Equipment Net	0.99	-0.39	0.94	0.96	0.96	1.0		0.8	0.94	-0.31	0.91	0.41	0.99	-0.11	0.29	0.77	0.97	-0.56	0.95	0.98	0.95	0.93	0.96	0.96	0.84	0.42
Current Deferred Revenue	0.74	-0.65	0.64	0.7	0.68	0.79	0.8		0.63	-0.19	0.8	0.33	0.75	0.13	0.28	0.62	0.74	-0.35	0.69	0.71	0.83	0.71	0.7	0.81	0.56	-0.04
Net Debt	0.98	-0.13	1.0	0.88	0.96	0.93	0.94	0.63		-0.32	0.75	0.43	0.97	-0.1	0.28	0.84	0.98	-0.59	0.99	0.96	0.85	0.94	0.99	0.83	0.91	0.62
Retained Earnings	-0.32	-0.06	-0.34	-0.35	-0.34	-0.29	-0.31	-0.19	-0.32		-0.35	-0.33	-0.32	0.73	-0.21	0.01	-0.38	0.44	-0.32	-0.32	-0.12	-0.45	-0.33	-0.3	-0.24	-0.16
Accounts Payable	0.85	-0.62	0.74	0.93	0.86	0.91	0.91	0.8	0.75	-0.35		0.17	0.86	-0.21	0.09	0.49	0.81	-0.48	0.74	0.86	0.91	0.78	0.79	0.97	0.58	0.23
Cash	0.46	0.18	0.5	0.34	0.34	0.4	0.41	0.33	0.43	-0.33	0.17		0.44	-0.31	0.93	0.45	0.51	-0.35	0.53	0.41	0.2	0.53	0.49	0.29	0.62	0.05
Non Current Assets Total	1.0	-0.29	0.98	0.95	0.97	0.99	0.99	0.75	0.97	-0.32	0.86	0.44		-0.11	0.31	0.8	0.99	-0.58	0.98	0.99	0.93	0.95	0.99	0.93	0.88	0.5
Non Currrent Assets Other	-0.11	-0.07	-0.12	-0.22	-0.18	-0.11	-0.11	0.13	-0.1	0.73	-0.21	-0.31	-0.11		-0.11	0.23	-0.13	0.58	-0.08	-0.12	0.08	-0.19	-0.11	-0.14	-0.04	-0.19
Cash And Short Term Investments	0.33	0.13	0.35	0.22	0.19	0.3	0.29	0.28	0.28	-0.21	0.09	0.93	0.31	-0.11		0.3	0.37	-0.01	0.4	0.29	0.11	0.38	0.35	0.19	0.47	-0.11
Net Receivables	0.81	-0.06	0.84	0.63	0.73	0.74	0.77	0.62	0.84	0.01	0.49	0.45	0.8	0.23	0.3		0.82	-0.42	0.86	0.76	0.73	0.76	0.84	0.62	0.91	0.42
Common Stock Total Equity	0.99	-0.22	0.98	0.92	0.95	0.96	0.97	0.74	0.98	-0.38	0.81	0.51	0.99	-0.13	0.37	0.82		-0.6	0.99	0.98	0.89	0.98	0.99	0.89	0.9	0.48
Short Term Investments	-0.57	0.08	-0.6	-0.58	-0.62	-0.54	-0.56	-0.35	-0.59	0.44	-0.48	-0.35	-0.58	0.58	-0.01	-0.42	-0.6		-0.57	-0.56	-0.48	-0.62	-0.59	-0.52	-0.48	-0.47
Non Current Liabilities Total	0.98	-0.15	0.99	0.87	0.93	0.94	0.95	0.69	0.99	-0.32	0.74	0.53	0.98	-0.08	0.4	0.86	0.99	-0.57		0.96	0.85	0.95	1.0	0.84	0.93	0.52
Inventory	0.99	-0.25	0.96	0.97	0.98	0.99	0.98	0.71	0.96	-0.32	0.86	0.41	0.99	-0.12	0.29	0.76	0.98	-0.56	0.96		0.92	0.94	0.98	0.93	0.87	0.53
Other Current Assets	0.92	-0.52	0.84	0.92	0.92	0.95	0.95	0.83	0.85	-0.12	0.91	0.2	0.93	0.08	0.11	0.73	0.89	-0.48	0.85	0.92		0.82	0.88	0.95	0.72	0.37
Other Stockholder Equity	0.95	-0.15	0.94	0.88	0.89	0.93	0.93	0.71	0.94	-0.45	0.78	0.53	0.95	-0.19	0.38	0.76	0.98	-0.62	0.95	0.94	0.82		0.95	0.86	0.86	0.42
Total Liab	0.99	-0.19	1.0	0.91	0.96	0.95	0.96	0.7	0.99	-0.33	0.79	0.49	0.99	-0.11	0.35	0.84	0.99	-0.59	1.0	0.98	0.88	0.95		0.87	0.92	0.56
Property Plant And Equipment Gross	0.92	-0.5	0.83	0.97	0.91	0.97	0.96	0.81	0.83	-0.3	0.97	0.29	0.93	-0.14	0.19	0.62	0.89	-0.52	0.84	0.93	0.95	0.86	0.87		0.71	0.31
Total Current Assets	0.9	0.07	0.93	0.78	0.84	0.83	0.84	0.56	0.91	-0.24	0.58	0.62	0.88	-0.04	0.47	0.91	0.9	-0.48	0.93	0.87	0.72	0.86	0.92	0.71		0.54
Short Term Debt	0.51	0.29	0.6	0.46	0.63	0.42	0.42	-0.04	0.62	-0.16	0.23	0.05	0.5	-0.19	-0.11	0.42	0.48	-0.47	0.52	0.53	0.37	0.42	0.56	0.31	0.54

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.8T	12.9T	13.2T	14.0T	16.1T	16.9T
Common Stock Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.4B	1.3B
Short Long Term Debt Total	5.1T	4.6T	4.3T	4.4T	5.0T	5.3T
Other Current Liab	682.3B	790.7B	1.4T	1.5T	1.7T	1.8T
Total Current Liabilities	2.2T	1.8T	2.1T	2.5T	2.9T	3.0T
Total Stockholder Equity	4.7T	5.2T	5.7T	6.4T	7.3T	7.7T
Property Plant And Equipment Net	1.4T	1.5T	1.6T	1.7T	1.9T	2.0T
Current Deferred Revenue	200.5B	119.5B	588.0B	616.5B	709.0B	744.4B
Net Debt	4.5T	3.7T	3.5T	3.8T	4.4T	4.6T
Retained Earnings	1.4T	1.5T	1.5T	1.5T	1.4T	1.4T
Accounts Payable	318.8B	343.8B	516.3B	649.2B	746.6B	783.9B
Cash	637.6B	966.2B	849.7B	533.5B	480.2B	597.2B
Non Current Assets Total	10.4T	10.2T	10.6T	11.6T	13.3T	14.0T
Non Currrent Assets Other	103.8B	100.3B	82.6B	63.3B	72.8B	69.2B
Cash And Short Term Investments	653.4B	1.0T	875B	553.7B	498.3B	737.6B
Net Receivables	784.9B	812.7B	724.4B	681.7B	783.9B	540.0B
Common Stock Total Equity	168.7B	1.6T	1.7T	1.7T	1.9T	2.0T
Short Term Investments	15.8B	36.6B	25.3B	20.2B	18.2B	17.2B
Liabilities And Stockholders Equity	12.8T	12.9T	13.2T	14.0T	16.1T	16.9T
Non Current Liabilities Total	5.9T	6.0T	5.3T	5.1T	5.9T	6.2T
Inventory	759.6B	753.9B	853.2B	986.5B	1.1T	1.2T
Other Current Assets	114.2B	122.8B	141.1B	160.9B	185.0B	194.2B
Other Stockholder Equity	1.6T	1.6T	1.6T	1.6T	1.9T	2.0T
Total Liab	8.1T	7.7T	7.5T	7.6T	8.7T	9.2T
Property Plant And Equipment Gross	1.4T	1.5T	2.5T	2.7T	3.1T	3.3T
Total Current Assets	2.5T	2.7T	2.6T	2.4T	2.8T	2.0T
Accumulated Other Comprehensive Income	92.6B	366.1B	934.2B	1.5T	1.7T	1.8T
Short Term Debt	586.8B	22.2B	204.0B	339.6B	390.5B	410.1B
Common Stock	1.7T	1.7T	1.7T	1.7T	1.9T	2.0T
Good Will	4.0T	4.0T	4.4T	4.8T	5.5T	5.8T
Intangible Assets	4.2T	3.9T	3.8T	4.3T	4.9T	5.2T
Other Assets	10.4T	454.1B	678.7B	429.3B	493.7B	469.0B
Other Liab	1.1T	831.0B	1.2T	544.1B	625.7B	713.1B
Net Tangible Assets	(3.8T)	(3.5T)	(2.8T)	(2.5T)	(2.3T)	(2.4T)
Long Term Debt	4.5T	4.6T	4.1T	4.0T	4.6T	2.9T
Long Term Investments	369.5B	348.4B	330.1B	378.9B	435.7B	286.4B
Short Long Term Debt	586.8B	22.2B	204.0B	339.6B	390.5B	328.0B
Treasury Stock	(74.4B)	(57.1B)	(87.5B)	(59.6B)	(53.6B)	(56.3B)
Property Plant Equipment	1.4T	1.5T	1.6T	1.7T	1.9T	1.1T
Long Term Debt Total	4.5T	4.6T	4.1T	4.0T	4.6T	3.3T

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.

Currently Active Assets on Macroaxis

MSFT	Microsoft
CRM	Salesforce
GOOG	Alphabet Inc Class C
V	Visa Class A
F	Ford Motor

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Takeda Stock analysis

When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.12)

Dividend Share

184

Earnings Share

0.36

Revenue Per Share

1.3 K

Quarterly Revenue Growth

0.013

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Takeda Retained Earnings vs Total Liab Analysis

Retained Earnings vs Total Liab

Retained Earnings vs Total Liab Correlation Analysis

Correlation Coefficient

Retained Earnings

Total Liab

Takeda Pharmaceutical fundamental ratios Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Takeda Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Property Plant And Equipment Net	+ 0.99	Total Assets

Current Deferred Revenue	- 0.65	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.62	Short Term Investments
Short Term Investments	- 0.62	Total Current Liabilities
Accounts Payable	- 0.62	Common Stock Shares Outstanding
Short Term Investments	- 0.6	Common Stock Total Equity
Short Term Investments	- 0.6	Short Long Term Debt Total